296. Biliary atresia
[
23 clinical trials,
37 drugs（DrugBank:
21 drugs),
35 target genes / 35 target pathways ]
Searched query = "Biliary atresia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900023843 | 2019-07-01 | 17 June 2019 | Effects of intestinal flora distribution and mucosal structure on pediatric liver transplantation with biliary atresia | Effects of intestinal flora distribution and mucosal structure on pediatric liver transplantation with biliary atresia | Biliary Atresia | 1:No;2:probiotics;3:Rifaximin; | Tianjin First Center Hospital | Not Recruiting | 0 | 18 | Both | 1:20;2:10;3:10; | Phase 0 | China | |
| 2 | NCT03563378 | July 28, 2018 | 2 July 2018 | Effects of Intraoperative Normal Saline vs Lactated Ringer on Outcomes in Pediatric Liver Transplantation | Effects of Intraoperative Normal Saline vs Lactated Ringer on Outcomes in Pediatric Liver Transplantation: A Double-blind Randomized Trial | Biliary Atresia Intrahepatic Syndromic Form | Drug: Lactated Ringer;Drug: Normal saline | RenJi Hospital | Recruiting | 3 Months | 6 Years | All | 200 | N/A | China | |
| 3 | ChiCTR-IOR-17013585 | 2018-06-14 | 16 July 2018 | Comparison of renal injury in children with liver transplantation under combined anesthesia with sevoflurane and propofol | The influence of sevoflurane and propofol on acute kidney injury in pediatric living donor liver transplantion | Congenital biliary atresia | P:Propofol compound anesthesia;Se:Sevoflurane compound anesthesia; | Tianjin First Central Hospital | Recruiting | 0.5 | 2 | Both | P:60;Se:60; | Other | China | |
| 4 | NCT03499249 | May 18, 2018 | 20 May 2019 | N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy | A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy | Biliary Atresia | Drug: N-Acetyl cysteine | Baylor College of Medicine | Recruiting | N/A | 90 Days | All | 16 | Phase 2 | United States | |
| 5 | ChiCTR1800015778 | 2018-04-20 | 30 April 2018 | Myocardial protection in pediatric patients undergoing liver transplantation | Myocardial protective strategies of pediatric liver transplantation with biliary atresia | Congenital biliary atresia | Propofol:Propofol compound anesthesia;Sev:Sev compound anesthesia; | Tianjin First Center Hospital | Recruiting | 0 | 2 | Both | Propofol:60;Sev:60; | Other | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03395028 | January 15, 2018 | 26 August 2019 | GCSF Adjunct Therapy for Biliary Atresia | Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia | Biliary Atresia | Drug: Granulocyte Colony-Stimulating Factor | Holterman, Ai-Xuan, M.D. | T Rose Clinical, Inc.;Children's National Health System | Not recruiting | N/A | 180 Days | All | 6 | Early Phase 1 | United States;Vietnam |
| 7 | JPRN-jRCTs041180088 | 01/12/2016 | 10 September 2019 | Influence of fatty acid metabolism for clinical course of biliary atresia | The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia | biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc. | oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid | Wataru Sumida | Hiroo Uchida | Recruiting | Not applicable | Not applicable | Both | 30 | N/A | none |
| 8 | ChiCTR-IPR-16008609 | 2016-07-01 | 12 June 2017 | Therapeutic effect of prophylactic intravenous antibiotics after Kasai procedure in biliary atresia | A clinical randomized controlled study to investigate the preventive effect of prophylactic intravenous antibiotics against cholangitis after Kasai procedure in biliary atresia | biliary atresia | Short-term Group:Cefoperazone 5 days;Long-term Group:Cefoperazone 14 days; | Children's Hospital of Fudan University | Not Recruiting | 0 | 1 | Both | Short-term Group:86;Long-term Group:86; | Post-market | China | |
| 9 | ChiCTR-OOC-16008707 | 2016-06-01 | 18 April 2017 | Study on pharmacodynamics of continuous infusion of rocuronium during transplantation of living donor liver transplantation for infants | Study on pharmacodynamics of continuous infusion of rocuronium during transplantation of living donor liver transplantation for infants | congenital biliary atresia | obstructive jaundice group:continuous infusion of rocuronium;after Kasai portoenterostomy group :continuous infusion of rocuronium; | Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University | Recruiting | Both | obstructive jaundice group:15;after Kasai portoenterostomy group :15; | Other | China | |||
| 10 | EUCTR2014-004693-42-GB | 29/06/2015 | 17 August 2015 | A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body. | A Multicenter, Randomized, Open Label, Single- and Multiple-Dose, Dose Finding Study and Open-Label Extension to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia | Biliary atresia MedDRA version: 18.0 Level: LLT Classification code 10004653 Term: Biliary atresia System Organ Class: 100000004850 MedDRA version: 18.0 Level: LLT Classification code 10004654 Term: Biliary atresia, congenital System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: OCA 1.5mg Product Code: OCA Pharmaceutical Form: Tablet INN or Proposed INN: obeticholic acid CAS Number: 459789-99-2 Current Sponsor code: OCA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Product Name: OCA 5mg Product Code: OCA Pharmaceutical Form: Tablet INN or Proposed INN: obeticholic acid CAS Number: 459789-99-2 Current Sponsor code: OCA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | Intercept Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 60 | United States;Canada;United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01854827 | October 2013 | 7 October 2019 | Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia | A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia | Biliary Atresia | Drug: Intravenous immunoglobulin (IVIG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | N/A | 120 Days | All | 30 | Phase 1/Phase 2 | United States;Canada | |
| 12 | NCT01774487 | January 2013 | 16 December 2017 | Pentoxifylline Therapy in Biliary Atresia | A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia | Biliary Atresia | Drug: Pentoxifylline | Baylor College of Medicine | Texas Children's Hospital | Recruiting | N/A | 180 Days | All | 60 | Phase 2 | United States |
| 13 | NCT02471209 | January 2012 | 29 June 2015 | Biliary Atresia, Hepatic Buffer Response and Sevoflurane | Biliary Atresia | Drug: Sevoflurane | Children's Hospital of Fudan University | Not recruiting | 1 Month | 3 Months | Both | 25 | N/A | |||
| 14 | NCT01443572 | September 2011 | 19 February 2015 | The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation | Kasai Operation;Biliary Atresia | Drug: desflurane anesthetics;Drug: sevoflurane anesthetics | Yonsei University | Not recruiting | N/A | 1 Year | Both | 40 | N/A | Korea, Republic of | ||
| 15 | NCT02137668 | July 2010 | 21 November 2016 | Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | Primary Sclerosing Cholangitis;Biliary Atresia | Drug: Oral Vancomycin | Sacramento Pediatric Gastroenterology | Recruiting | N/A | 40 Years | Both | 200 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2009-014886-21-NL | 26/01/2010 | 19 March 2012 | Intraoperative bile duct visualisation in children with biliary atresia using a fluorescence camera system: a pilot study - Bile duct mapping with fluorescence in BA | Intraoperative bile duct visualisation in children with biliary atresia using a fluorescence camera system: a pilot study - Bile duct mapping with fluorescence in BA | Biliary atresia | Trade Name: ICG-Pulsion 25mg Product Name: ICG Pulsion Product Code: VO4CX Pharmaceutical Form: Emulsion for injection | University Medical Centre Groningen | Authorised | Female: yes Male: yes | 4 | Netherlands | ||||
| 17 | NCT02298218 | September 2009 | 19 February 2015 | Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia | Biliary Atresia, Kasai Portoenterostomy Status | Drug: Meloxicam | Yonsei University | Not recruiting | 2 Years | 17 Years | Both | 50 | Phase 4 | |||
| 18 | NCT01322386 | May 2007 | 19 October 2017 | Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin. | Primary Sclerosing Cholangitis;Biliary Atresia | Drug: Vancomycin | Stanford University | Not recruiting | 1 Month | 20 Years | All | 32 | Phase 1 | ||
| 19 | ChiCTR-TNRC-09000331 | 2007-01-01 | 18 April 2017 | Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru | Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru | Biliary Atresia | group 1:Given Yinzhihuang with Ligustrazine from the day 3 after operation;group 2:Given Yinzhihuang with placebo from the day 3;group A:Divide two groups according different glucocorticoid, group A is given dexamethasone from the seventh day after operation;group B:Divide two groups according different glucocorticoid, group B is given methylprednisolone from the seventh day after operation; | The First Affiliated Hospital of Sun Yat Sen University | Not Recruiting | Both | group 1:50;group 2:50;group A:50;group B:50; | Post-market | China | |||
| 20 | NCT00294684 | November 2005 | 28 October 2019 | A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy | A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia | Biliary Atresia | Drug: Corticosteroids;Drug: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | N/A | 6 Months | All | 141 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT00166868 | December 2003 | 19 February 2015 | Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy | Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia | Biliary Atresia | Drug: Lactobacillus casei rhamnosus (Lcr35);Drug: Neomycin | National Taiwan University Hospital | Not recruiting | 4 Months | 3 Years | Both | 30 | N/A | Taiwan | |
| 22 | NCT00007033 | October 2000 | 19 February 2015 | Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease | Alagille Syndrome;Cholestasis;Biliary Atresia | Drug: magnesium gluconate;Drug: magnesium sulfate | National Center for Research Resources (NCRR) | Children's Hospital Medical Center, Cincinnati | Not recruiting | 3 Years | 18 Years | Both | 25 | N/A | United States | |
| 23 | NCT00539565 | January 2000 | 19 February 2015 | RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia. | Phase IIIb Study of Corticosteroids as Post-Operative Adjuvant Therapy in Biliary Atresia | Biliary Atresia | Drug: prednisolone;Drug: placebo | King's College Hospital NHS Trust | Recruiting | N/A | 100 Days | Both | 100 | Phase 3 | United Kingdom |